Low-Dose IL-2 Regimen for Treg-Selective Lupus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies for autoimmune diseases carry the risk of activating effector T cells that mediate the disease, leading to adverse effects and limited efficacy, and have not been effectively investigated for treating systemic lupus erythematosus.
Innovation Solution
Administering low doses of IL-2, ranging from 0.05 to 3.5 MIU/day, specifically targeting regulatory T cells (Tregs) to stimulate their expansion and activation without substantially inducing effector T cells (Teffs), thereby shifting the Treg/Teff balance in favor of Tregs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of IL-2 are administered to stimulate effector T cells for cancer treatment, then anti-tumor immune response is enhanced, but regulatory T cells are suppressed and auto-immune diseases are aggravated
Solution Approach 1:
The patent applies parameter changes by administering IL-2 at low doses (0.01-10 million international units per day, preferably 0.1-1 million international units per day) rather than high doses. This dose parameter change selectively stimulates regulatory T cells without significantly activating effector T cells, thereby treating autoimmune diseases while avoiding the aggravation of auto-immune responses that occurs with high-dose IL-2 therapy
2Object-affected harmful factors
If IL-2 is administered to stimulate regulatory T cells to reduce auto-immune responses, then immune suppression is enhanced, but effector T cell function may be compromised
Solution Approach 1:
The patent uses parameter changes by optimizing the IL-2 dosage to a low range (0.01-10 million international units per day) that selectively expands regulatory T cells while maintaining effector T cell function. This dose is sufficient to stimulate Treg development and homeostasis but insufficient to significantly activate effector T cells, thus resolving the contradiction between immune suppression and effector function
Solution Approach 2:
The patent applies local quality by creating different stimulation conditions for different T cell populations through low-dose IL-2 administration. Regulatory T cells receive sufficient IL-2 stimulation for expansion and activation, while effector T cells receive sub-threshold stimulation that maintains their function without significant activation, achieving selective modulation of immune cell populations
3Reliability
If IL-2 is administered at conventional doses for cancer therapy, then effector T cell activation is achieved, but the treatment is not suitable for autoimmune diseases due to risk of aggravating the disease
Solution Approach 1:
The patent applies parameter changes by establishing a new dosage parameter regime (0.01-10 million international units per day, preferably 0.1-1 million international units per day) that is fundamentally different from conventional cancer therapy doses. This parameter change makes IL-2 therapy adaptable to autoimmune diseases by selectively stimulating regulatory T cells without the harmful effects on effector T cells that occur at higher doses
Solution Approach 2:
The patent demonstrates universality by showing that IL-2 therapy can serve multiple functions depending on the dosage: at low doses (0.01-10 million international units per day) it selectively expands regulatory T cells for autoimmune disease treatment, while at higher doses it activates effector T cells for cancer therapy. This multi-functionality resolves the contradiction by allowing the same drug to be adapted to different disease contexts through dosage adjustment
Data Source
Figure 1A~2D
Figure 3~4
Figure 5~7C
AI summary
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.